| abstract |
Dicarbamate compounds as inhibitors of NS5A, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs, and pharmaceutical compositions thereof, are useful in treating diseases and disorders caused by the hepatitis C virus in humans, including cirrhosis and liver cancer. |